![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 32, 28870-28876, August 9, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 12, 2002, and in revised form, May 14, 2002
c-Abl is a non-receptor tyrosine kinase
implicated in DNA damage-induced cell death and in growth factor
receptor signaling. To further understand the function and
regulation of c-Abl, a yeast two-hybrid screen was performed to
identify c-Abl-interacting proteins. Here we report the identification
of Abl-philin 2 (Aph2), encoding a novel protein with a unique
cysteine-rich motif (zf-DHHC) and a 53-amino acid
stretch sharing homology with the creatine kinase family. The
zf-DHHC domain is highly conserved from yeast to human. Two
proteins containing this motif, Akr1p and Erf2p, have been
characterized in Saccharomyces cerevisiae, both implicated in signaling pathways. Deletion analysis by two-hybrid assays revealed
that the N-terminal portion of Aph2 interacts with the C terminus of
c-Abl. Aph2 was demonstrated to interact with c-Abl by
co-immunoprecipitation assays. Aph2 is expressed in most tissues tested
and is localized in the cytoplasm, mainly in the endoplasmic reticulum
(ER). The sequences required for ER location reside in the N
terminus and the zf-DHHC motif of Aph2. It has been
reported that a portion of c-Abl is localized in the ER. We demonstrate here that Aph2 and c-Abl are co-localized in the ER region.
Overexpression of Aph2 leads to apoptosis as justified by TUNEL assays,
and the induction of apoptosis requires the N terminus. Co-expression of c-Abl and Aph2 had a synergistic effect on apoptosis induction and
led to a decreased expression of both proteins, suggesting either that
these two proteins are mutually down-regulated or that cells expressing
both c-Abl and Aph2 rapidly disappeared from the culture. These
results suggest that Aph2 may be involved in ER stress-induced
apoptosis in which c-Abl plays an important role.
c-Abl is a ubiquitously expressed non-receptor tyrosine kinase.
This protein has Src homology domains (SH1, SH2, and
SH3)1 at the N terminus and a
DNA binding domain, an actin binding domain, three nucleus localization
signals, and a proline-rich motif at the C terminus (reviewed in Refs.
1 and 2). The C terminus is essential for c-Abl function and is a
unique feature not found in other Src family members. c-Abl is
localized in both the nucleus and the cytoplasm. Movement between these
two compartments may play an important role in regulating c-Abl
function (3, 4). c-Abl is activated by DNA damage, oxidative stress,
cell adhesion to extracellular matrix, growth factors, and Src family kinases (reviewed in Refs. 1 and 2). However, the physiological function of c-Abl is not well understood. Mice lacking c-Abl showed perinatal death, runtedness, reduced fertility, lymphopenia, and osteoporosis (5-7). Arg (Abl-related protein), a c-Abl homologue, has
a similar structure (8). Arg( c-Abl plays an important role in apoptosis (1). Ectopic expression of
c-Abl in fibroblasts causes apoptosis in a p53-independent manner (10,
11). Epithelial cells stably expressing a mutant c-Abl without kinase
activity (K290R) are resistant to apoptosis induced by either
anti-metabolite 1- Many c-Abl-interacting proteins have been identified (reviewed in Ref.
17). Some are prominent substrates for c-Abl
(e.g. Abi1/Abi2, Crk1/CrkL, RNA polymerase II,
p62dok, and p73), and some of them are not (e.g.
p53, Rb, 3BP-1/3BP-2, AAP1, ATM and DNA-PK, PAG) (18). Some of
the interacting proteins, such as PAG and Rb, were found to
negatively regulate c-Abl kinase activity and function, whereas others,
such as RFXI, an EP-DNA-binding protein that potentiates the kinase
activity when bound to c-Abl, were found to be positive regulators for
c-Abl (19).
In this study we identified a novel c-Abl-interacting protein, Aph2, by
a two-hybrid screen. The protein has a cysteine-rich domain that is
conserved in many proteins from yeast to mammals. Aph2 is ubiquitously
expressed in tissues tested and is mainly localized in the ER of cells.
When ectopically expressed, Aph2 induces apoptosis. c-Abl and Aph2 have
a synergistic effect in apoptosis induction. These results indicate
that Aph2 may cooperate with c-Abl in induction of apoptosis.
Yeast Two-hybrid Screen--
To produce a bait protein, a type I
c-Abl cDNA fragment (encoding 1091 residues) was subcloned into
pSH2-1 to form the LexA DNA binding domain fusion protein. The bait
construct was introduced by the standard LiAc-polyethylene glycol
method into a yeast strain, CTY10-5D, which carried in its genome a
Northern Analysis--
The tissue distribution of Aph2 was
determined by Northern analysis. A blot that contains mRNA from
different tissues (CLONTECH) was probed with
radio-labeled Aph2. The probe was random primer-labeled full-length
Aph2 cDNA.
Cell Culture and Transfection--
COS-7 and NIH3T3 cells were
grown in Dulbecco's modified Eagle's medium containing 10% fetal
calf serum supplemented with glutamine and penicillin. For
transfection, DNA isolated with the Maxi-DNA purification kit (Qiagen)
was used to transform cells by the lipofectAMINE method
following the manufacturer's protocol (Invitrogen).
To express c-Abl, the open reading frame of type IV c-Abl was cloned
into the expression vector pMT21 (21) without any epitope tag (a stop
codon was retained in c-Abl). To express Aph2, the open reading frame
of Aph2 was synthesized by PCR and cloned into pSR Immunoprecipitation and Western Blot--
Transfected cells were
washed with cold PBS and lysed in TNEN buffer (50 mM
Tris-HCl, pH 7.5, 50 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml
each of pepstatin, leupeptin, and aprotinin). The lysate was clarified by centrifugation at 10,000 × g for 10 min at 4 °C.
Aph2 was immunoprecipitated with monoclonal anti-myc
antibody 9E10 (Santa Cruz Biotechnology) and recovered by protein
G-agarose. c-Abl was precipitated with polyclonal antibodies
(K-12) (Santa Cruz Biotechnology), raised against the kinase
domain of c-Abl, and recovered with protein A-agarose. The precipitate
was washed in TNEN buffer three times, boiled in 1× loading buffer,
and separated on a SDS-PAGE gels. Proteins were transferred to
immobilon-P nitrocellulose membranes (Millipore), and Western blot was
carried out by standard protocol and visualized with ECL (Amersham
Biosciences). To detect protein phosphorylation after c-Abl
transfection, cells were lysed in TNEN buffer containing 0.5 mM sodium orthovanadate and 1 mM NaF. To
detect phosphorylated proteins on nitrocellulose blots, an anti-phosphorylated tyrosine antibody (RC20:HRPO, Transduction Laboratories) was used.
Immunohistochemistry--
COS or NIH3T3 cells growing on
coverslips were transfected with lipofectAMINE. After 24 h, the
cells were permeablized with methanol at TUNEL Assay--
COS-7 or NIH3T3 cells were transfected with
vector DNA expressing Aph2 by the lipofectAMINE method. Cells
cultured for 24 h after transfection were fixed in 10% formalin
and then assayed for apoptosis using a kit from Oncor, which uses
horseradish peroxidase-conjugated antibodies. Counter-staining was
performed with Methyl Green.
Quantitation of Apoptotic Cells--
COS-7 or NIH3T3 cells were
transfected with pCR3.1cmv-galactosidase (23) and plasmids expressing
c-Abl, Aph2, or both and were cultured for 24 h. Plates were
washed with PBS and fixed in a phosphate buffer containing formaldehyde
and paraldehyde for 5 min at room temperature. In each transfection,
empty vectors (PSR Cloning and Expression of Aph2--
To search for
c-Abl-interacting proteins, a yeast two-hybrid screen was carried out.
The nearly full-length type I c-Abl (aa 1-1091) was used as bait and
fused to the DNA binding domain of LexA. The library consists of
fusions between the GAL4 activation domain and cDNAs isolated from
WEHI-3 myeloid lymphoma. A total of one million yeast colonies were
screened, and four were found to carry one previously unidentified gene
named Aph2 for abl-philin 2. The gene was also isolated in a
separate screen using a C-terminal portion of Abl as bait (20). To
obtain the full-length cDNA, the 5'-terminal DNA of an initial
two-hybrid clone (a 400-bp fragment) was used to screen a mouse liver
cDNA library. Clones were isolated, subcloned into pBluescript, and
sequenced. The longest cDNA sequence has been deposited to
GenBankTM (accession number AF176814), and the predicted
protein sequence is shown in Fig.
1A. The Aph2 gene
encodes a 361-amino acid protein.
Aph2 protein shows no strong homology to any known proteins in
GenBankTM. A search of the expression data base revealed
that Aph2 has a homologue in the human (AAH04535). A search for domains using the domain architecture retrieval tool (DART) revealed two distinct domains, zf-DHHC (aa 157-210) (24) and a 53-amino
acid sequence (aa 205-257) homologous to the consensus sequence of ATP:guanido phosphotransferase, represented by creatine kinase. The
zf-DHHC domain is distinct from the Zinc-finger, LIM, and Ring finger domains and is found in many proteins including Akr1p and
Erf2p, both of which are involved in signaling pathways in Saccharomyces cerevisiae (25-28). Fig. 1B shows
the alignment of five such proteins. Creatine kinase is the major
enzyme in vertebrates that converts creatine to phosphocreatine using
ATP as phosphate donor. Phosphocreatine is responsible for transporting
energy from the site of ATP synthesis and is also used as an energy
buffer (29).
Northern analysis was carried out to determine the expression pattern
of Aph2 in mouse tissues. Fig.
2A shows that Aph2 has two
transcripts, a major one that is ~2 kb in size and a minor one of
~3.5 kb. The 2-kb mRNA probably corresponds to the cDNA of
Aph2, whereas the 3.5-kb mRNA may represent an alternatively spliced form. Aph2 is expressed in all tissues examined, with a much
weaker expression in the spleen. The commercial blot has an even
loading of RNA from different tissue as judged by probing with actin
(20). The ubiquitous expression suggests that the Aph2 protein may play
a fundamental role in cell physiology. To test the expression of Aph2
at the protein level, Aph2 was tagged with glutathione
S-transferase or maltose-binding protein (MBP) at the N
terminus and was expressed in bacteria. A band migrating at a portion
of markers >200 kDa was detected on a SDS-PAGE gel (data not shown),
suggesting that Aph2 protein exists as aggregates. To express Aph2 in
mammalian cells, Aph2 was Myc-tagged at the C terminus. When expressed
in COS-7 cells, Aph2 again was found to migrate as a >200-kDa protein
on SDS-PAGE gels (Fig. 2B). It may be a multimer or a
conjugate with other proteins through disulfide bonds because the
zf-DHHC motif has many cysteine residues. The behavior was
unusual for proteins boiled in SDS in the presence of reducing agents.
Addition to the lysis buffer of 100 mM dithiothreitol or
treatment with 1 mM iodoacetamide did not improve the
solubility of Aph2. Lysis in radioimmune precipitation assay (RIPA)
buffer also gave similar results. However, proper expression of Aph2 was confirmed by the observation that a fusion protein between MBP and
Aph2 ran at the correct size (Fig. 2B). This result also suggests that addition of MBP to the N-terminal end may have disrupted the tertiary structure of Aph2 and therefore made the protein incapable
of conjugating with other proteins. Deletion of the cysteine-rich
domain also resulted in a protein that runs at correct molecular weight
on SDS-PAGE gel (Fig. 2C). An N-terminal fragment of Aph2
(aa 1-226) and a C-terminal fragment of Aph2 (aa 150-361) also were
expressed correctly. These data indicate that Aph2 can be expressed
correctly in mammalian cells, although it may exist in a form of
oligomer or in a form of conjugate with other proteins.
c-Abl Interacts with Aph2--
To determine which domain of the
protein interacts with c-Abl, different portions of Aph2 were fused
in-frame to the DNA binding domain of LexA, and two hybrid assays were
carried out (Fig. 3A). We
found that any deletion of Aph2 dramatically reduced its affinity for
c-Abl. Several fragments truncated at the C terminus displayed quite
strong interactions as long as the zf-DHHC domain was
retained, whereas all deletions of the N terminus, even in the presence of the zf-DHHC domain, completely abolished the interaction.
These results suggest that the N-terminal portion of the protein is important for interaction with c-Abl, although no obvious
protein-protein interaction motif is apparent. Similarly, different
portions of c-Abl were fused to the DNA binding domain of GAL4 to
identify the domains important for the interaction (Fig.
3B). We used the full-length Aph2 fused to the LexA
activation domain. These assays suggested that the C-terminal portion
of c-Abl interacts with Aph2.
To confirm the interaction in mammalian cells, type IV c-Abl and Aph2
were co-expressed in COS-7 cells, and co-immunoprecipitation assays
were performed. First, Aph2-Myc and associated proteins were
immunoprecipitated with antibody against the c-Myc tag, fractionated on
an 8% SDS-PAGE gel, and transferred to nitrocellulose membrane. The
blot was probed with antibodies against c-Abl. As shown in Fig.
3C, c-Abl was brought down with Aph2, although pre-immune serum did not precipitate c-Abl. In cells that only express c-Abl anti-Myc antibody did not precipitate c-Abl, confirming the interaction between c-Abl and Aph2 (data not shown). Reciprocally, c-Abl and associated proteins were precipitated with anti-c-Abl antibodies, separated on an 8% SDS-PAGE gel, and transferred to nitrocellulose membrane. The blot was probed with anti-Myc antibody (Fig.
3D). Aph2 was brought down by c-Abl, whereas the pre-immune
serum did not bring down Aph2. In cells that only express Aph2,
anti-c-Abl antibodies did not precipitate Aph2 (data not shown).
These data suggest that there is an interaction between c-Abl and Aph2
in mammalian cells.
Aph2 is not an efficient substrate for c-Abl. In COS-7 cells
co-expressing Aph2 and c-Abl, Aph2 was immunoprecipitated using anti-Myc antibody, and tyrosine phosphorylation was determined by
Western blot using antibodies that specifically recognize
phosphotyrosine. We could not detect any phosphorylated Aph2, although
c-Abl autophosphorylation and Abi-1 phosphorylation could be detected
easily using the same setting (data not shown).
Localization of Aph2--
To study the function of Aph2, the
cellular localization of the protein was determined by indirect
fluorescent immunocytochemistry using the Myc-tagged Aph2.
In COS-7 cells Aph2 was detected exclusively in the cytoplasm,
especially in the perinuclear region, which is indicative of
endoplasmic reticulum (Fig. 4,
A and B). To confirm that Aph2 is localized in
the ER, an ER-specific dye (DiOC6) was used. As shown in Fig. 4,
C-E, strong co-staining exists between Aph2 and
ER. We found no obvious ER retention signal in the Aph2 protein. We
next tested for the co-localization of Aph2 and c-Abl. Fig. 4,
F-H shows that c-Abl and Aph2 are
co-localized, although c-Abl is also localized near the cell surface
and in the nucleus of some cells. Our results are consistent with a
recent report suggesting that Abl resides on ER and that upon ER stress
Abl may translocate to mitochondria and induce apoptosis (30). The localization of Aph2 to the ER suggests that it may play a role related
to the ER function of c-Abl.
Using various deletions, we found that the C-terminal portion of Aph2
(aa 226-361) expressed separately was dispersed throughout the
cytoplasm, in contrast to the strong perinuclear staining of other
fragments of Aph2 (aa 1-226, 150-361, and deletion of the
zf-DHHC region) (Fig. 5).
These data suggest that more than one signal for ER location may exist,
with one residing in the N-terminal portion and another in the
zf-DHHC region.
Ectopic Expression of Aph2 Leads to Apoptosis--
Immunostaining
for Aph2 in both COS-7 (Fig. 4, A and B) and
NIH3T3 (data not shown) revealed an interesting aspect of Aph2 function. Both cell types expressing Aph2 were round and smaller, with
the nuclei condensed. Some of the cells show nuclei with abnormal
shapes, suggesting that theses cells are undergoing apoptosis (Fig.
4B). In these cells, Aph2 is organized in a unique structure that is exclusive of the nucleus. In some cells, nuclei were split into
two by Aph2. The cells transfected with vector alone did not show this
phenotype. To confirm that these cells were apoptotic, TUNEL assays
were performed. As shown in Fig.
6A, COS cells transfected with
vector were not apoptotic, whereas many Aph2 transfected cells were
stained positive for apoptosis.
Aph2 and c-Abl Work Synergistically in the Induction of
Apoptosis--
To quantitate apoptosis, an assay was adopted in which
the transfected surviving cells were counted (23). In this assay, cells
are transfected with genes of interest and a construct that expresses
To confirm the apoptotic effect of c-Abl and Aph2 using the
quantitative assay, COS cells were transfected with 1.0 µg of DNA
expressing c-Abl, 0.4 µg of DNA expressing Aph2, or both, along with
0.2 µg of pCR3.1cmv-galactosidase DNA per well in six-well plates.
After 36 h, the plates were washed with PBS, fixed in paraformaldehyde/formalin, permeabilized, and stained with X-gal at
37 °C. After the color had developed, plates were washed with and
stored in PBS.
Both the N portion and the C portion of Aph2 were tested in the
quantitative apoptosis assay. The N terminus Aph2 had a similar effect
on apoptosis as the full-length protein, whereas the C terminus had
little effect on apoptosis (Fig. 6C). Co-expression of c-Abl
with the N terminus of Aph2 also had a synergistic effect, while the
C-terminal Aph2 had a much weaker effect (Fig. 6C). These
results suggest that the apoptotic effect of Aph2 can be executed
by its N portion.
Overexpression of c-Abl leads to apoptosis in many cells lines, and
this effect does not require kinase activity; the kinase-defective c-Abl mutant also causes apoptosis when overexpressed (10). To test
whether the synergistic effect of c-Abl and Aph2 requires the kinase
activity a c-Abl mutant, K290R, was used in similar experiments as
shown in Fig. 6B. We did not detect a significant difference
between wild type and the mutant c-Abl at 1.0 µg per well (Fig.
6C). The mutant c-Abl also had a synergistic effect on
apoptosis with Aph2, confirming that the kinase activity is not
involved in this aspect of c-Abl function.
Expression of Aph2 and c-Abl Is Mutually
Down-regulated--
In the course of co-expression experiments of
c-Abl and Aph2, we noted a profound effect of high level expression of
each protein on the other. At a constant level of c-Abl DNA and
increasing amounts of Aph2 DNA, we noticed that the c-Abl expression
level was reduced dramatically by the expression of Aph2 (Fig.
7). Similarly, when cells were
transfected with a fixed amount of Aph2 DNA, increasing the amount of
c-Abl DNA dramatically reduced the level of Aph2 expression (data not
shown). On the other hand, Abi-1, another c-Abl-interacting protein,
did not down-regulate c-Abl expression when co-expressed (data not
shown). These results suggest either that cells co-expressing Aph2 and
c-Abl have a higher tendency to undergo apoptosis, that Aph2 and c-Abl
proteins are mutually down-regulated, or both. The results shown in
Fig. 6 favor the conclusion that down-regulation is attributable to a
loss from the cultures of those cells expressing the two proteins,
resulting from the synergistic effects of c-Abl and Aph2 on apoptosis
induction. Aph2 is under the control of a hybrid SV40/HTLV
promoter, and c-Abl is under the control of the adenovirus major late
promoter. The down-regulation could not be explained by competition for transcriptional machinery. The C portion of Aph2, under the control of
the same promoter, did not have a similar effect. The N portion of Aph2
did down-regulate the expression of c-Abl (data not shown). These
results on apoptosis induction (Fig. 6C), and
down-regulation of c-Abl obtained with truncated forms of Aph2 also
support our conclusion that the down-regulation is attributable to a
loss from the cultures of those cells expressing both c-Abl and
Aph2.
We have cloned and characterized a novel gene, aph2,
encoding a c-Abl-interacting protein. This protein has a cysteine-rich motif (zf-DHHC) that is found in many proteins from yeast to
human. Most of these protein sequences are predicted from genomic DNA sequences and therefore are not well characterized. Other cysteine-rich motifs include the better-known Zinc finger, Ring finger, and LIM
domains. Although Zinc finger domains often are involved in protein-DNA
interaction, both Ring finger and LIM are involved in protein-protein
interactions. In addition, Ring finger domains also play an important
role in protein ubiquitination and degradation. The zf-DHHC
motif of Aph2 probably does not bind DNA because Aph2 was localized in
the ER. Two yeast proteins (Akr1p and Erf2p) containing the
motif were not localized in the nucleus either. The motif may be
involved in disulfide bond formation inter- or intra-molecularly. Aph2
expressed in either bacteria or mammalian cells is prone to aggregation
and runs as a >200 KD band on SDS-PAGE gels.
Deletion of the domain facilitated the solubilization of Aph2.
The functions of zf-DHHC-bearing proteins may be diverse.
Two such proteins from yeast have been characterized to date, Akr1p and
Erf2p. Akr1p interacts physically with the pheromone
receptor-coupled G protein, and a genetic interaction has been observed
with cdc42p and also with an ARF GAP, Gcs1(25-27, 32). Erf2p is
required for the proper localization and palmitoylation of Ras proteins
in yeast (28). These proteins do not suggest any simple role for the
motif. Another clue regarding zf-DHHC function is that in some proteins it co-exists with ankyrin repeats, which are important for protein-protein interactions, e.g. Akr1p and an
uncharacterized protein (NP-014667) of S. cerevisiae, a hypothetical protein (T33870) of
Caenorhabditis elegans, a hypothetical protein
(AAF48554) of Drosophila melanogaster, and
an uncharacterized protein (NP_061901) of human. Whether a functional
connection exists between zf-DHHC and ankyrin repeats is
unclear. Two more mammalian proteins containing zf-DHHC also
have been deposited into GenBankTM. One is named as rec
(reduced expression in cancer, accession number NP_057437), and the
other is a protein from the human pancreatic library (C16ORF1). The
function of either rec or C16ORF1 is not known.
Aph2 has a 53-amino acid stretch sharing homology with ATP:guanido
phosphotransferase consensus sequence found in creatine and arginine
kinases. The homology resides in domain I (N-terminal) of the creatine
kinase family, comprising How does overexpression of Aph2 induce apoptosis? Based on the
localization of Aph2 and the fact that cyclosporin A could not protect
cells from apoptosis induced by Aph2 (data not shown), it is likely
that Aph2 induces apoptosis in an ER stress-related pathway.
Accumulation of misfolded proteins or an alteration in calcium
homeostasis causes ER stress, which leads to apoptosis of cells if the
damages are not fixed. Caspase 12 is localized in the ER and is
responsible for ER stress-induced apoptosis. Bcl2, an anti-apoptotic
protein, also was found to be located in the ER in addition to
mitochondria. Depletion of ER calcium by the overexpression of Bcl2
plays an important anti-apoptotic role (33). Overexpression of Aph2
somehow may stress the ER and subsequently induce apoptosis. Whether
Aph2 affects protein folding or calcium homeostasis needs to be
studied. c-Abl has been implicated to play a role in ER stress-induced
apoptosis (30). c-Abl was found to be located in the ER, and treatment with tunicamycin or Brefeldin A led to translocation of c-Abl from the ER to mitochondria.
Aph2 has a synergistic effect on apoptosis induction with c-Abl. What
are the mechanisms that underlie the synergy? Unfortunately, even the
mechanisms under which overexpression of c-Abl induces apoptosis are
still unclear. One hypothesis is that apoptosis is caused by the
nuclear c-Abl, while the cytoplasmic c-Abl may play an anti-apoptotic
effect, as seen with v-Abl and Bcr-Abl, both of which are localized
solely in the cytoplasm (1). Recent experiments demonstrated that
Bcr-Abl, once brought into the nucleus, could induce apoptosis, thus
supporting this hypothesis (16). We propose that Aph2 may block the
anti-apoptotic effect of cytoplasmic c-Abl by physical interaction
while allowing the nuclear c-Abl to act. There are other
c-Abl-interacting proteins that also are involved in apoptosis. p53
and p73, both of which interact with c-Abl and induce apoptosis when
ectopically expressed, have a synergistic effect on apoptosis induction
(10, 31).
We thank Sharon Boast, Kenia de los Santos,
Hong In Ian, and Dr. Tang Bor Luen for technical assistance.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF176814, NP_057437, and C16ORF1.
¶
A Cancer Research Institute fellow.
**
An investigator from the Howard Hughes Medical Institute.
Published, JBC Papers in Press, May 20, 2002, DOI 10.1074/jbc.M202388200
2
B. Li and S. P. Goff, unpublished data.
The abbreviations used are:
SH, Src homology;
ER, endoplasmic reticulum;
aa, amino acids;
Aph2, Abl-philin 2;
PBS, phosphate-buffered saline;
FITC, fluorescein isothiocyanate;
TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling;
X-gal, 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside;
MBP, maltose-binding protein.
Aph2, a Protein with a zf-DHHC Motif, Interacts with
c-Abl and Has Pro-apoptotic Activity*
§¶,
,
,
, and
Institute of Molecular and Cell Biology,
National University of Singapore, 30 Medical Drive, Singapore 117609 and the Departments of
Biology and § Biochemistry and
Molecular Biophysics, Howard Hughes Medical Institute, Columbia
University, New York, New York 10032
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/
) mice develop normally, whereas
embryos deficient in both Abl and Arg suffer from defects in
neurulation and die before 11 days postcoitum (9).
-D-arabinofuranosylcystine (ara-C) or
ionizing radiation (12, 13). Furthermore, c-Abl-null mouse
embryonic fibroblasts showed resistance to apoptosis induced by the
same treatments (14). These findings provide evidence for a
pro-apoptotic function of c-Abl. On the other hand, c-Abl has also been
demonstrated to have an anti-apoptotic effect. Pre-B lymphocytes
isolated from c-Abl-null mice are more sensitive to IL-7 withdrawal or
glucocorticoid-induced apoptosis (15). Osteoblasts from c-Abl-null mice
also are more sensitive to free radical-induced cell
death.2 In these two cell
types, c-Abl apparently protects cells from cell death. Furthermore,
the oncogenic form of c-Abl (BCR-ABL) is anti-apoptotic, and the
anti-apoptotic activity could be due to the cytoplasmic localization of
BCR-ABL (16).
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-galactosidase reporter under the regulation of a LexA promoter. The
library of cDNAs was derived from the murine myeloid cell line
WEHI-3 and was transferred into pGADNOT (20). To screen for
c-Abl-interacting proteins, the library was used to transform CTY10-5D
carrying the bait and was selected on
Leu
His
plates. Interaction was detected by
staining for
-galactosidase activity on nitrocellulose replicas. To
identify the sequences of Aph2 that interact with c-Abl, different
portions of Aph2 cDNA were synthesized by PCR and subcloned into
pGADNOT and then were transformed into CTY10-5D carrying the bait.
-galactosidase activity was detected on the nitrocellulose replica.
(22) such that
the expression protein was tagged by c-myc peptide at the C
terminus. To make various deletions of Aph2, PCR-synthesized mutant
versions were subcloned into pSR
similarly.
20 °C for 3 min, washed
three times with PBS containing 10% bovine calf serum, and incubated
with the primary antibodies for 1 h at room temperature. 9E10 was
used to detect Aph2, and K-12 was used to detect c-Abl. After
interaction with the primary antibody, the slides were washed three
times with PBS containing 10% bovine calf serum and then incubated
with secondary antibody conjugated with FITC or Texas Red (Sigma) for
1 h at room temperature. DAPI (4',6-diamidino-2-phenylindole) was
used to stain the nucleus, and DioC6 was used to stain the ER. The
slides were then washed with PBS and examined under a confocal microscope.
or pMT21) were used to make up the same amount of
DNA. After being washed in phosphate buffer containing Nonidet P-40,
cells were stained with X-gal at 37 °C. When the blue color
developed, plates were washed and kept in PBS.
-galactosidase-positive cells were counted at 40 ×10 magnification
for five fields of view that represented the surviving cells. For
NIH3T3, surviving cells were counted from seven fields of view at the
magnification of 10 ×10 because of lower transfection efficiency.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (79K):
[in a new window]
Fig. 1.
A, protein sequences of Aph2. The
zf-DHHC domain is in red, and the cysteine
residues and DHHC are in blue. The protein sequence
homologous to creatine kinase is underlined. B,
alignment of the zf-DHHC domains from a few proteins.
Shaded residues, identity; bold, conserved
residues.

View larger version (63K):
[in a new window]
Fig. 2.
Expression of Aph2. A, Northern
blot analysis showing the expression of Aph2 in different tissues.
B, Western blot showing Aph2 and MBP-Aph2 expressed in COS
cells. DNAs expressing wild type and mutant versions of Aph2
were used to transfect COS cells with lipofectAMINE, and cells were
lysed after 36 h. Cell lysates were run on SDS-PAGE gel, and Aph2
and mutants were detected with an anti-Myc antibody. C,
Western blot showing the expression of mutant Aph2 proteins.

View larger version (27K):
[in a new window]
Fig. 3.
Interaction between aph2 and c-Abl.
Deletion analysis of Aph2 using two-hybrid interaction.
A and B, plasmids expressing different mutant
forms of Aph2 were introduced into CTY10-5D that was already
expressing a LexA-Abl fusion.
-galactosidase activity was measured
as an indicator for interaction. (+++), dark blue after
1 h at 30 °C; (+), light blue after 4 h; (
),
no blue after 24 h. C, c-Abl can be
co-immunoprecipitated with Aph2. COS cells co-expressing c-Abl and Aph2
were harvested 36 h after the start of transfection and were lysed
in TNEN buffer. Aph2 was precipitated with anti-Myc antibody,
and c-Abl was detected with anti-c-Abl antibody K-12. D,
Aph2 co-immunoprecipitated with c-Abl. COS cells co- expressing c-Abl
and Aph2 were lysed, c-Abl was precipitated with K-12, and Aph2 was
detected with anti-Myc antibody 9E10. IP, immunoprecipitate.
NLS, nuclear localization signal; PTK, protein
tyrosine kinase.

View larger version (69K):
[in a new window]
Fig. 4.
Co-localization of Aphz and c-Abl in the ER.
A, localization of Aph2. COS cells were transfected with DNA
expressing Myc-tagged Aph2 by lipofectAMINE as described under
"Materials and Methods." After 24 h, cells were fixed
and incubated with anti-Myc antibody, 9E10, followed by DAPI
(4',6-diamidino-2-phenylindole) (B) and anti-mouse
conjugated with FITC (A). C-E,
localization of Aph2 in ER. COS cells were transfected with DNA
expressing Myc-tagged Aph2 and then were stained with DiOC6 for ER
(C) and anti-Myc plus secondary anti-mouse antibodies
conjugated with Texas Red (D). F-H,
Co-localization of Aph2 and c-Abl. COS cells were transfected to
express Aph2 and c-Abl and were stained with anti-Myc and secondary
anti-mouse conjugated with Texas Red (G) and anti-Abl plus
secondary anti-rabbit conjugated with FITC (F).

View larger version (71K):
[in a new window]
Fig. 5.
Localization of various Aph2 truncation
mutants. Different truncated forms of Aph2 were fused to Myc tag
and expressed in COS cells. After 24 h, cells were stained for ER
and Aph2 as described in the legend to Fig. 4.

View larger version (64K):
[in a new window]
Fig. 6.
A, TUNEL assay showing that Aph2 has
pro-apoptotic activity. COS cells were transfected with 1.0 µg of
DNA as indicated for 36 h, fixed in 10% formalin, and then
stained for DNA breakage using an apoptosis kit from Oncor.
B, Aph2 and c-Abl cooperate to induce apoptosis. Cells in
six-well plates were transfected with 0.2 µg of
pCR3.1cmv-galactosidase and DNAs expressing either nothing, c-Abl,
Aph2, or both, and cultured for 24 h. Cells were fixed and stained
for
-galactosidase. Positive cells represent the surviving cells.
C, effects of c-Abl kinase-defective mutant and Aph2 mutants
on apoptosis induction.
-galactosidase. If the expression of the gene of interest causes apoptosis, the number of
-galactosidase-positive cells will
be reduced. This method has been used successfully to study the effect
of c-Abl on apoptosis and in other cases (10). In our experiments, we
used both COS-7 and NIH3T3 cells. The data presented below are from
COS-7 cells because of its high transfection efficiency, but similar
results were obtained from these two cell lines.
-galactosidase-positive cells were counted from five
randomly chosen views under the magnification of ×400. Each experiment
was repeated three times. Although the transfection efficiency varied
slightly, the percentage of transfected cells that survived was similar
(Fig. 6B). c-Abl at 1.0 µg did not have any significant
effect on apoptosis in COS-7 cells. When c-Abl was increased to 3.0 µg, the proportion of apoptotic cells was dramatically increased to
40% (data not shown), consistent with previous results (10). Aph2 at
0.4 µg was a stronger inducer of apoptosis with 25% of the
transfected cells dead. Co-expression of c-Abl and Aph2 (1.0 and 0.4 µg, respectively) had a much stronger effect on apoptosis (65%
transfected cells dead) than the combination of individual expression,
suggesting that c-Abl and Aph2 have a synergistic effect. This also was
confirmed by our observation that more cells have condensed nuclei when
c-Abl and Aph2 are co-expressed in NIH3T3 cells (data not shown).
Similarly, both p53 and p73 were found to induce more apoptosis when
co-expressed with c-Abl (10, 31).

View larger version (43K):
[in a new window]
Fig. 7.
Down-regulation of c-Abl by expression of
Aph2. COS cells were transfected with 0.5 µg of DNA expressing
type IV c-Abl, 1.0 µg of DNA expressing c-Abl, and an increasing
amount of DNA expressing Myc-tagged Aph2. Cells were collected 36 h from the start of transfection and were lysed in TNEN buffer. 20 µg
of total proteins were separated on an 8% SDS-PAGE gel and transferred
to Immobilon nitrocellulose membrane. The blot was probed with 9E10 to
detect Aph2 and with K-12 to detect c-Abl.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-helices 4 and 5, which may be involved in
substrate interaction. Domain II is important for ATP binding and
enzymatic activity (29). Because Aph2 has homology to only 53 amino
acids of the 380-amino acid consensus sequence, it is unlikely that
Aph2 plays a role in the energy buffer or transport system.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

To whom correspondence should be addressed: Dept. of
Biochemistry and Molecular Biophysics, HHSC 1310c, Columbia University, College of Physicians and Surgeons, 701 W. 168th St., New York, NY
10032; Tel.: 212-305-7956; Fax: 212-305-8692; E-mail: goff@ cancercenter.columbia.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Wang, J. Y.
(2000)
Oncogene
19,
5643-5650[CrossRef][Medline]
[Order article via Infotrieve]
2.
Van Etten, R. A.
(1999)
Trends Cell Biol.
9,
179-186[CrossRef][Medline]
[Order article via Infotrieve]
3.
Lewis, J. M.,
Baskaran, R. F.,
Taagepera, S.,
Schwartz, M. A.,
and Wang, J. Y.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15174-15179 4.
Taagepera, S.,
McDonald, D. F.,
Loeb, J. E.,
Whitaker, L. L.,
McElroy, A. K.,
Wang, J. Y.,
and Hope, T. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7457-7462 5.
Schwartzberg, P. L.,
Stall, A. M.,
Hardin, J. D.,
Bowdish, K. S.,
Humaran, T. F.,
Boast, S.,
Harbison, M. L.,
Robertson, E. J.,
and Goff, S. P.
(1991)
Cell
65,
1165-1175[CrossRef][Medline]
[Order article via Infotrieve]
6.
Tybulewicz, V. L.,
Crawford, C. E.,
Jackson, P. K.,
Bronson, R. T.,
and Mulligan, R. C.
(1991)
Cell
65,
1153-1163[CrossRef][Medline]
[Order article via Infotrieve]
7.
Li, B.,
Boast, S.,
de los Santos, K.,
Schieren, I.,
Quiroz, M.,
Teitelbaum, S. L.,
Tondravi, M. M.,
and Goff, S. P.
(2000)
Nat. Genet.
24,
304-308[CrossRef][Medline]
[Order article via Infotrieve]
8.
Kruh, G. D.,
Perego, R.,
Miki, T.,
and Aaronson, S. A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
5802-5806 9.
Koleske, A. J.,
Gifford, A. M.,
Scott, M. L.,
Nee, M.,
Bronson, R. T.,
Miczek, K. A.,
and Baltimore, D.
(1998)
Neuron
21,
1259-1272[CrossRef][Medline]
[Order article via Infotrieve]
10.
Theis, S.,
and Roemer, K.
(1998)
Oncogene
17,
557-564[CrossRef][Medline]
[Order article via Infotrieve]
11.
Cong, F.,
and Goff, S. P.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13819-13824 12.
Huang, Y.,
Yuan, Z. M.,
Ishiko, T.,
Nakada, S.,
Utsugisawa, T.,
Kato, T.,
Kharbanda, S.,
and Kufe, D. W.
(1997)
Oncogene
15,
1947-1952[CrossRef][Medline]
[Order article via Infotrieve]
13.
Yuan, Z. M.,
Huang, Y.,
Ishiko, T.,
Kharbanda, S.,
Weichselbaum, R.,
and Kufe, D.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1437-1440 14.
Gong, J. G.,
Costanzo, A.,
Yang, H. Q.,
Melino, G.,
Kaelin, W. G., Jr.,
Levrero, M.,
and Wang, J. Y.
(1999)
Nature
399,
806-809[CrossRef][Medline]
[Order article via Infotrieve]
15.
Dorsch, M.,
and Goff, S. P.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13131-13136 16.
Vigneri, P.,
and Wang, J. Y.
(2001)
Nat. Med.
7,
228-234[CrossRef][Medline]
[Order article via Infotrieve]
17.
Raitano, A. B.,
Whang, Y. E.,
and Sawyers, C. L.
(1997)
Biochim. Biophys. Acta
1333,
F201-F216[Medline]
[Order article via Infotrieve]
18.
Wen, S. T.,
and Van Etten, R. A.
(1997)
Genes Dev.
11,
2456-2467 19.
Agami, R.,
and Shaul, Y.
(1998)
Oncogene
16,
1779-1788[CrossRef][Medline]
[Order article via Infotrieve]
20.
Shi, Y.,
Alin, K.,
and Goff, S. P.
(1995)
Genes Dev.
9,
2583-2597 21.
Takebe, Y.,
Seiki, M.,
Fujisawa, J.,
Hoy, P.,
Yokota, K.,
Arai, K.,
Yoshida, M.,
and Arai, N.
(1988)
Mol. Cell. Biol.
8,
466-472 22.
An, D. S.,
Koyanagi, Y.,
Zhao, J. Q.,
Akkina, R.,
Bristol, G.,
Yamamoto, N.,
Zack, J. A.,
and Chen, I. S.
(1997)
J. Virol.
71,
1397-1404[Abstract]
23.
Liu, Z. G.,
Hsu, H.,
Goeddel, D. V.,
and Karin, M.
(1996)
Cell
87,
565-576[CrossRef][Medline]
[Order article via Infotrieve]
24.
Putilina, T.,
Wong, P.,
and Gentleman, S.
(1999)
Mol. Cell. Biochem.
195,
219-226[CrossRef][Medline]
[Order article via Infotrieve]
25.
Givan, S. A.,
and Sprague, G., Jr.
(1997)
Mol. Biol. Cell
8,
1317-1327[Abstract]
26.
Kao, L. R.,
Peterson, J., Ji, R.,
Bender, L.,
and Bender, A.
(1996)
Mol. Cell. Biol.
16,
168-178[Abstract]
27.
Pryciak, P. M.,
and Hartwell, L. H.
(1996)
Mol. Cell. Biol.
16,
2614-2626[Abstract]
28.
Bartels, D. J.,
Mitchell, D.,
Dong, X.,
and Deschenes, R. J.
(1999)
Mol. Cell. Biol.
19,
6775-6787 29.
Wyss, M.,
and Kaddurah-Daouk, R.
(2000)
Physiol. Rev.
80,
1107-1213 30.
Ito, Y.,
Pandey, P.,
Mishra, N.,
Kumar, S.,
Narula, N.,
Kharbanda, S.,
Saxena, S.,
and Kufe, D.
(2001)
Mol. Cell. Biol.
21,
6233-6242 31.
Agami, R.,
Blandino, G.,
Oren, M.,
and Shaul, Y.
(1999)
Nature
399,
809-813[CrossRef][Medline]
[Order article via Infotrieve]
32.
Feng, Y.,
and Davis, N. G.
(2000)
Mol. Cell. Biol.
20,
5350-5359 33.
Pinton, P.,
Ferrari, D.,
Rapizzi, E., Di,
Virgilio, F. D.,
Pozzan, T.,
and Rizzuto, R.
(2001)
EMBO J.
20,
2690-2701[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. Fernandez-Hernando, M. Fukata, P. N. Bernatchez, Y. Fukata, M. I. Lin, D. S. Bredt, and W. C. Sessa Identification of Golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase J. Cell Biol., July 31, 2006; 174(3): 369 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Ducker, L. K. Griffel, R. A. Smith, S. N. Keller, Y. Zhuang, Z. Xia, J. D. Diller, and C. D. Smith Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Mol. Cancer Ther., July 1, 2006; 5(7): 1647 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Piwocka, S. Vejda, T. G. Cotter, G. C. O'Sullivan, and S. L. McKenna Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling Blood, May 15, 2006; 107(10): 4003 - 4010. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Swarthout, S. Lobo, L. Farh, M. R. Croke, W. K. Greentree, R. J. Deschenes, and M. E. Linder DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras J. Biol. Chem., September 2, 2005; 280(35): 31141 - 31148. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zeng, Y. Hu, and B. Li Identification of TopBP1 as a c-Abl-interacting Protein and a Repressor for c-Abl Expression J. Biol. Chem., August 12, 2005; 280(32): 29374 - 29380. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Politis, A. F. Roth, and N. G. Davis Transmembrane Topology of the Protein Palmitoyl Transferase Akr1 J. Biol. Chem., March 18, 2005; 280(11): 10156 - 10163. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Saitoh, Q. B. Tian, A. Okano, H. Sakagami, H. Kondo, and T. Suzuki NIDD, a Novel DHHC-containing Protein, Targets Neuronal Nitric-oxide Synthase (nNOS) to the Synaptic Membrane through a PDZ-dependent Interaction and Regulates nNOS Activity J. Biol. Chem., July 9, 2004; 279(28): 29461 - 29468. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Keller, X. Yuan, P. Panzanelli, M. L. Martin, M. Alldred, M. Sassoe-Pognetto, and B. Luscher The {gamma}2 Subunit of GABAA Receptors Is a Substrate for Palmitoylation by GODZ J. Neurosci., June 30, 2004; 24(26): 5881 - 5891. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Linder and R. J. Deschenes Model organisms lead the way to protein palmitoyltransferases J. Cell Sci., February 15, 2004; 117(4): 521 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lobo, W. K. Greentree, M. E. Linder, and R. J. Deschenes Identification of a Ras Palmitoyltransferase in Saccharomyces cerevisiae J. Biol. Chem., October 18, 2002; 277(43): 41268 - 41273. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||